Showing results (21-30 of 138) with videos related to
Sort By:
Pageof 14
Immunotherapy|July 17, 2018
Oncolytic herpes simplex virus immunovirotherapy in combination with immune checkpoint blockade to treat glioblastomaDipongkor Saha, Robert L Martuza, Samuel D RabkinMethods in Molecular Biology (Clifton, N.J.)|October 17, 2019
Preparation of Herpes Simplex Virus Type 1 (HSV-1)-Based Amplicon VectorsCornel Fraefel, Alberto L EpsteinThe Open Virology Journal|September 3, 2010
Constitutive and Inducible Innate Responses in Cells Infected by HSV-1-Derived Amplicon VectorsEliza Tsitoura, Alberto L EpsteinCurrent Gene Therapy|December 8, 2004
Herpesvirus/retrovirus chimeric vectorsAlberto L Epstein, Roberto ManservigiCurrent Gene Therapy|June 22, 2006
Amplicon vectors as outstanding tools to study and modify cognitive functionsDiana Jerusalinsky, Alberto L EpsteinNeurosurgical Focus|July 7, 2007
Oncolytic herpes simplex virus therapy for peripheral nerve tumorsDeva S Jeyaretna, Samuel D Rabkin, Robert L MartuzaFuture Oncology (London, England)|April 9, 2010
Oncolytic herpes simplex virus vectors and chemotherapy: are combinatorial strategies more effective for cancer?Ryuichi Kanai, Hiroaki Wakimoto, Tooba Cheema, et al.Oncoimmunology|March 26, 2019
Triple threat to cancer: rationale for combining oncolytic viruses, MEK inhibitors, and immune checkpoint blockadePraveen K Bommareddy, Samuel D Rabkin, Howard L KaufmanMedecine Sciences : M/S|June 11, 2015
[Herpes simplex virus type 1 latency and reactivation: an update]Alejandro M Aranda, Alberto L EpsteinCell|August 18, 2023
Herpes simplex virus gene therapy for dystrophic epidermolysis bullosa (DEB)Alberto L Epstein, Cornelia Haag-MolkentellerPageof 14